New numbers from Ottawa and Queen’s Park offer two approaches to managing a strained economy — but few new ideas.

My valuation reflects the current market price, however investors should proceed with caution and take into consideration ...

The class action lawsuit says the Milwaukee-based financial tech provider compelled its customers to shift to its newer ...

Delivers Third Quarter Net Sales of $753.1 Million, Driven by Acthar® Gel (repository corticotropin injection) Growth and the Inclusion of Two Months of ...

Annualized recurring revenue ("ARR") of $838 million, an increase of 2% year-over-yearTotal revenue of $218 million, up 2% year-over-year; Product subscriptions revenue of $210 million, up 2% year-ove ...

Members of the diplomatic community, business and industry representatives, the K92 Board of Directors, project partners and industry peers were also in attendance. As at September 30, 2025, 90% of ...

The North Carolina state auditor has long been influential, but the office has worked more like a coroner than an EMT. Auditors tended to show up after something went wrong, carefully pieced together ...

Understand earnings calls: structure, Q&A, management tone, and key metrics investors track for performance, guidance, and ...

COM701 Phase 1 data presented at ESMO 2025 characterized patients who derived clinical benefit and informed the design of the ongoing MAIA-ovarian ...

Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine MonthRevenue of $135.8 Million, up 11% Year-over-Year; Adjusted EBITDA of $34.2 Million, up 35% Year-over-Year Positive Outlook ...

Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC Received FDA IND clearance for ARR-217, a CDH-17 ...